Research programme: PASylated cytokine - XL-protein GmbH
Latest Information Update: 09 Aug 2016
At a glance
- Originator XL-protein GmbH
- Developer International Biotechnology Center Generium; XL-protein GmbH
- Class Cytokines
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 09 Aug 2016 No recent reports on development identified for Undefined indication in Germany, Russia, Commonwealth of Independent States (unspecified route)